$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000110465914036131 Filed on May 08, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$0.00
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.061M	$3.000M	$3.730M
YoY Change	46.7%	20.0%	109.55%
% of Gross Profit
Research & Development	$4.534M	$4.652M	$7.280M
YoY Change	76.01%	73.58%	199.59%
% of Gross Profit
Depreciation & Amortization	$100.0K	$66.00K	$60.00K
YoY Change	100.0%	40.43%	50.0%
% of Gross Profit
Operating Expenses	$9.595M	$7.650M	$11.01M
YoY Change	59.36%	47.83%	161.52%
Operating Profit	-$9.595M	-$7.650M
YoY Change	59.36%	47.83%
Interest Expense	-$320.0K	-$150.0K	$10.00K
YoY Change	-1166.67%	-850.0%	-50.0%
% of Operating Profit
Other Income/Expense, Net	$24.00K	-$10.00K
YoY Change
Pretax Income	-$9.890M	-$7.810M	-$11.00M
YoY Change	64.83%	51.36%	162.53%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$9.893M	-$7.814M	-$11.00M
YoY Change	64.99%	51.52%	162.53%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$98.90	-$86.77	-$137.50
COMMON SHARES
Basic Shares Outstanding	24.20M shares	18.56M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$81.40M	$89.50M	$44.40M
YoY Change	49.91%	49.92%	41.4%
Cash & Equivalents	$16.55M	$56.13M	$18.08M
Short-Term Investments	$64.80M	$33.30M	$26.30M
Other Short-Term Assets	$1.200M	$600.0K	$700.0K
YoY Change	33.33%	20.0%	16.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$82.60M	$90.07M	$45.08M
YoY Change	49.47%	49.66%	41.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.900M	$1.202M	$880.0K
YoY Change	113.48%	34.3%	16.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.100M	$1.403M	$1.500M
YoY Change
Other Assets	$200.0K	$100.0K	$100.0K
YoY Change	127.27%	13.64%	7.53%
Total Long-Term Assets	$3.200M	$2.693M	$2.468M
YoY Change	227.2%	173.96%	190.69%
TOTAL ASSETS
Total Short-Term Assets	$82.60M	$90.07M	$45.08M
Total Long-Term Assets	$3.200M	$2.693M	$2.468M
Total Assets	$85.80M	$92.76M	$47.55M
YoY Change	52.56%	51.66%	44.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.400M	$1.943M	$1.654M
YoY Change	548.15%	104.96%	89.03%
Accrued Expenses	$5.600M	$4.344M	$4.120M
YoY Change	250.88%	279.06%	240.21%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.100M	$6.287M	$5.774M
YoY Change	291.83%	200.24%	176.8%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$100.0K	$74.00K	$70.00K
YoY Change	566.67%	572.73%	900.0%
Total Long-Term Liabilities	$100.0K	$74.00K	$70.00K
YoY Change	566.67%	572.73%	900.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.100M	$6.287M	$5.774M
Total Long-Term Liabilities	$100.0K	$74.00K	$70.00K
Total Liabilities	$7.100M	$6.361M	$5.844M
YoY Change	288.62%	202.19%	179.22%
SHAREHOLDERS EQUITY
Retained Earnings			-$45.18M
YoY Change			180.02%
Common Stock		$23.00K	$18.00K
YoY Change		27.78%	38.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$78.70M	$86.40M	$41.70M
YoY Change
Total Liabilities & Shareholders Equity	$85.80M	$92.76M	$47.55M
YoY Change	52.56%	51.66%	44.89%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q4
OPERATING ACTIVITIES
Net Income	-$9.893M	-$7.814M	-$11.00M
YoY Change	64.99%	51.52%	162.53%
Depreciation, Depletion And Amortization	$100.0K	$66.00K	$60.00K
YoY Change	100.0%	40.43%	50.0%
Cash From Operating Activities	-$6.570M	-$4.960M	-$4.680M
YoY Change	27.33%	22.17%	34.1%
INVESTING ACTIVITIES
Capital Expenditures	$1.160M	$0.00	$210.0K
YoY Change	2220.0%	-100.0%	40.0%
Acquisitions
YoY Change
Other Investing Activities	-$31.84M	-$8.640M	$1.970M
YoY Change	225.56%		-111.8%
Cash From Investing Activities	-$33.00M	-$8.640M	$1.760M
YoY Change	235.37%	4700.0%	-110.45%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$51.70M
YoY Change		58.1%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-20.00K	51.66M	-80.00K
YoY Change		58.22%	300.0%
NET CHANGE
Cash From Operating Activities	-6.570M	-4.960M	-4.680M
Cash From Investing Activities	-33.00M	-8.640M	1.760M
Cash From Financing Activities	-20.00K	51.66M	-80.00K
Net Change In Cash	-39.59M	38.06M	-3.000M
YoY Change	163.93%	33.97%	-85.26%
FREE CASH FLOW
Cash From Operating Activities	-$6.570M	-$4.960M	-$4.680M
Capital Expenditures	$1.160M	$0.00	$210.0K
Free Cash Flow	-$7.730M	-$4.960M	-$4.890M
YoY Change	48.37%	16.87%	34.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	ovas	Cash And Money Market Funds Fair Value CashAndMoneyMarketFundsFairValue	18078000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	44417000	USD
CY2013Q4	ovas	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	13000	USD
CY2013Q4	ovas	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	3000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	44427000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18078000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	18078000	USD
CY2013Q4	ovas	Cash Cash Equivalents And Marketable Securities Amortized Cost CashCashEquivalentsAndMarketableSecuritiesAmortizedCost	44417000	USD
CY2014Q1	ovas	Cash And Money Market Funds Amortized Cost CashAndMoneyMarketFundsAmortizedCost	56134000	USD
CY2014Q1	ovas	Cash And Money Market Funds Fair Value CashAndMoneyMarketFundsFairValue	56134000	USD
CY2014Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	89465000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3048000	shares
CY2014Q1	ovas	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	9000	USD
CY2014Q1	ovas	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	12000	USD
CY2013Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2014Q1	ovas	Cash Resources Sufficient To Fund Current Operating Plan CashResourcesSufficientToFundCurrentOperatingPlan	89500000	USD
CY2014Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3048000	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4309000	shares
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">These condensed consolidated financial statements are presented in conformity with U.S. generally accepted accounting principles which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.</font></p> </div>
CY2014Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2014Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2014Q1	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2014Q1	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2013Q4	ovas	Cash And Money Market Funds Amortized Cost CashAndMoneyMarketFundsAmortizedCost	18078000	USD
CY2014Q1	us-gaap	Assets Assets	92763000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1654000	USD
CY2014Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	89462000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56134000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	56134000	USD
CY2014Q1	ovas	Cash Cash Equivalents And Marketable Securities Amortized Cost CashCashEquivalentsAndMarketableSecuritiesAmortizedCost	89465000	USD
CY2013Q4	ovas	Cash Cash Equivalents And Marketable Securities Fair Value CashCashEquivalentsAndMarketableSecuritiesFairValue	44427000	USD
CY2014Q1	ovas	Cash Cash Equivalents And Marketable Securities Fair Value CashCashEquivalentsAndMarketableSecuritiesFairValue	89462000	USD
CY2014Q1	ovas	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Number Of Securities AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsNumberOfSecurities	10	item
CY2014Q1	ovas	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Number Of Securities AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerNumberOfSecurities	0	item
CY2014Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	13900000	USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8600000	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y5M12D
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Short Term Investments ShortTermInvestments	26349000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	650000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	45077000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	880000	USD
CY2013Q4	us-gaap	Equity Method Investments EquityMethodInvestments	1500000	USD
CY2013Q4	us-gaap	Assets Assets	47545000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4120000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5774000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	70000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	5844000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	6361000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6287000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	90070000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	86851000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	10000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-45178000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	41701000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47545000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	86402000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	92763000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	7000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-3000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52995000	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9270000	shares
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-5157000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-52992000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5150000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7827000	USD
CY2013Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108000	USD
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18528215	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17541126	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24167656	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23345082	shares
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2680000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27947000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2495000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24990000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	5175000	USD
	us-gaap	Operating Expenses OperatingExpenses	52937000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	7650000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-52937000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5175000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7650000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	66000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	364000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	47000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	390000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-7814000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	-101000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5157000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-53093000	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7814000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.73
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13345000	shares
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	812000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	837000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7689000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-97000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	605000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1555000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	73000	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-61000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4419000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4056000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-35771000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4961000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	184000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1568000	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	4415000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	48945000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	88000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-184000	USD
CY2014Q1	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	41192000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51661000	USD
CY2014Q1	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1500000	USD
CY2013Q4	ovas	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Number Of Securities AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsNumberOfSecurities	8	item
CY2013Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	9500000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32652000	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	41091000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	51661000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	32652000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	129207000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	38056000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	28412000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	56134000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14776000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43188000	USD
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24202656	shares
CY2014Q1	us-gaap	Short Term Investments ShortTermInvestments	33331000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	605000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1202000	USD
CY2014Q1	us-gaap	Equity Method Investments EquityMethodInvestments	1403000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1500000	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	88000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	88000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-45000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1401000	USD
CY2014Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	228000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	4415000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1943000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4344000	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	74000	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	23000	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	139374000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4652000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2998000	USD
CY2014Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-57000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000	USD
CY2014Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-97000	USD
CY2013Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	18000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	52000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-97000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19214000	shares
CY2014Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	149000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	867000	USD
	ovas	Issuance Of Common Stock For Technology Access Fee IssuanceOfCommonStockForTechnologyAccessFee	2500000	USD
CY2013Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2013Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2014Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	4714000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	10384000	USD

Files In Submission

Name	View Source	Status
0001104659-14-036131-index-headers.html	Edgar Link	pending
0001104659-14-036131-index.html	Edgar Link	pending
0001104659-14-036131.txt	Edgar Link	pending
0001104659-14-036131-xbrl.zip	Edgar Link	pending
a14-9604_110q.htm	Edgar Link	pending
a14-9604_1ex10d1.htm	Edgar Link	pending
a14-9604_1ex31d1.htm	Edgar Link	pending
a14-9604_1ex31d2.htm	Edgar Link	pending
a14-9604_1ex32d1.htm	Edgar Link	pending
a14-9604_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
ovas-20140331.xml	Edgar Link	completed
ovas-20140331.xsd	Edgar Link	pending
ovas-20140331_cal.xml	Edgar Link	unprocessable
ovas-20140331_def.xml	Edgar Link	unprocessable
ovas-20140331_lab.xml	Edgar Link	unprocessable
ovas-20140331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2014 Q2 Form 10-Q Financial Statement

#000110465914036131 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2014 Q2 Form 10-Q Financial Statement

#000110465914036131 Filed on May 08, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst